Evaluating the levels of interleukin-6 and interleukin-10 as potential biomarkers for the severity and mortality in COVID-19 patients

https://doi.org/10.53730/ijhs.v6nS8.9714

Authors

  • Mohammed Dakhil Bareez Al-Hatemy Al-Najaf health directorate, Department of operations and emergency medicine
  • Muslim Idan Mohsin Department Laboratory Investigation, Faculty of science, University of Kufa

Keywords:

COVID-19, IL-6, IL-10

Abstract

Objective: Evaluating the levels of pro-inflammatory cytokine (IL-6) and anti-inflammatory cytokine (IL-10) among patients with COVID-19. Methodology: A study is conducted during the period from 1st November 2021 to 1 st April 2022 , 110 patients were diagnosed as COVID-19. Their ages range between 20-81 and more years old, Who attended to AL-Amal Specialized Hospital for Communicable Diseases at first week of  infection with symptoms (fever, Headache, cough, shortness of breath, diarrhea, loss of taste and smell), and compared with 50 apparently healthy individuals as control group. The diagnosis of each case was established using clinical diagnosis and confirmed by reverse transcriptase polymerase chain reaction (rt-PCR), 5 ml of fresh venous blood samples were collected from COVID-19 infected patients by sterile syringes and saved in serum separator tube (SST) with specific gel to easy sorting the serum, then left for 20 minutes at room temperature. After coagulation, sera were separated by centrifuge 4000xg for 15 minutes and directly stored at -20 ºC to be analyzed later for IL-6 and IL-10 assay. 

Downloads

Download data is not yet available.

References

Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections cause and consequences of cytokine storm and immunopathology. Semin Immunopathol., 39(5): 529-539.

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. J. Am. Med. Assoc., 324:782–93.

Perlman, S., Netland, J. (2009). Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol., 7:439–50.

Wang, F., Nie, J., Wang, H., Zhao, Q. et al. (2020). Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis., 221, 1762–1769.

Al-Samkari, H. & Berliner, N. (2018). Hemophagocytic lymphohistiocytosis. Annu. Rev. Pathol. 13, 27–49.

Mangalmurti, N. & Hunter, C. A. (2020). Cytokine storms: understanding COVID-19. Immunity, 53, 19–25.

Bogdan, C., Vodovotz, Y. & Nathan, C. (1991). Macrophage deactivation by interleukin 10. J. Exp. Med., 174, 1549–1555.

Khadke, S., Ahmed, N., Ahmed, N., Ratts, R., Raju, S., Gallogly, M., de Lima, M. and Sohail, M.R. (2020). harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. J. Virol., 17(1):1-18.

AL-Roubaey, D. A. A. (2017). The correlation between oral warfarin intake and two proinflammatory cytokines (IL-6 and TNF-α ) and their effects on atherosclerosis in deep venous thrombosis disease. Al-Kufa University Journal for Biology, 87-94.

Maeda, T., Obata, R., Rizk, D.O. D. et al. (2021). The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J. Med. Virol., 93:463–71.

Buonaguro, F. M., Puzanov, I., Ascierto, P. A. (2020). Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med., 18:165.

McGonagle, D., Sharif, K., O'Regan, A. and Bridgewood, C. (2020). “The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease,” Autoimmunity Reviews, 19(6), article 102537.

Hunter, C. A., and Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nat. Immunol., 16(5): 448-457.

Burian, E., Jungmann, F., Kaissis, G. A. , Lohöfer, F.K., Spinner, C.D., Lahmer, T., et al. (2020). Intensive care risk estimation in COVID-19 pneumonia based on clinical and imaging parameters: experiences from the Munich cohort. J. Clin. Med., 9:1514.

Chi, Y., Ge, Y., Wu, B., et al. (2020). Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 (COVID-19) in China. J. Infect Dis., jiaa363.

AL-Roubaey, D. A. A. (2018). Clinical measures for cytokine levels after and before hirudotherapy in rheumatoid arthritis patients. Journal of Global Pharma Technology, (10):3 578-586.

Saraiva, M. & O’Garra, A. (2010). The regulation of IL-10 production by immune cells. Nat. Rev. Immunol., 10, 170–181.

Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., Geginet, J. (2010). Biology of interleukin-10. Cytokine Growth Factor Rev, 21(5):331–44.

Diao, B. et al. (2020). Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol., 11 , p. 827.

Hu, W. (2020). Use interleukin-10 as the therapeutic agent for COVID-19. OSF Preprint at https://doi.org/10.31219/osf.io/arfhb.

Lu, L., Zhang, H., Zhan, M., Jiang, J. et al. (2020). Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm? Front. Cell Dev. Biol., 8: 677.

Zhao, Y., Qin, L., Zhang, P., Li, K., Liang, L., Sun, J. et al. (2020). Longitudinal profiling of cytokines and chemokines in COVID-19 reveals inhibitory mediators IL-1Ra and IL-10 are associated with disease severity while elevated RANTES is an early predictor of mild disease. JCI Insight, 5 (13) Article e139834.

Lauw, F. N., Pajkrt, D., Hack, C. E., Kurimoto, M., van Deventer, S. J. H., van der Poll, T. (2000). Proinflammatory Effects of IL-10 During Human Endotoxemia. J. Immunol ., 165:2783–9.

Wu, F., Liu, M., Wang, A., Lu, L., Wang, Q., Gu, C. et al. (2020). Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA. Intern. Med., 180:1356-62.

Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., and Gierke, R. (2020). Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, MMWR., 69(12): 343-346.

Leij-Halfwerk, S., Verwijs, M. H., van Houdt, S., Borkent, J. W., Guaitoli, P. R., Pelgrim, T. et al. (2019). Prevalence of protein-energy malnutrition risk in European older adults in community, residential and hospital settings, according to 22 malnutrition screening tools validated for use in adults ≥65 years: a systematic review and meta-analysis. Maturitas, 126:80–9.

Volkert, D., Beck, A. M., Cederholm, T., Cereda, E., Cruz-Jentoft, A., Goisser, S. et al. (2019). Management of Malnutrition in older patients—current approaches, evidence and open questions. J. Clin. Med., 8:974.

Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M. et al. (2019). Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol., 10:2247.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., and Cheng, Z. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223): 497-506.

Guan, W.J., Liang, W.H., Zhao, Y., Liang, H.R., Chen, Z.S., Li, Y.M., Liu, X.Q., Chen, R.C., Tang, C.L., Wang, T., and Ou, C.Q. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J., 55; (5): 2000547.

Chen, N., Zhou, M., Dong, X. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223):507–513.

Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y.D., Yang, Y.B., Yan, Y. Q., Akdis, C. A., and Gao, Y. D. (2020). Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan-China. Allergy, 75(7):1730-1741.

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., and Zhou, Y. (2020). Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int. J. Infect. Dis., 94:91-5.

Rezzani, R., Nardo, L., Favero, G., Peroni, M., and Rodella, L.F. (2014). Thymus and aging: a morphological, radiological, and functional overview. Age, 36(1): 313-351.

Thapa, P., and Farber, D. L. (2019). The role of the thymus in the immune response. Thorac. Surg. Clin., 29(2):123-131.

Clerkin, K. J., . Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., Schwartz, A., Uriel, N. (2020). COVID-19 and cardiovascular disease. Circulation, 141(20): 1648–1655.

Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., and Wu, J. C. (2020). COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 17: 543–558.

Chan, J. W., Ng, C. K., Chan, Y. H., Mok, T. Y., Lee, S., Chu, S. Y., Law, W. L., Lee, M. P., Li, P. C. (2003). Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS).Thorax., 58:686–689.

Booth, C. M., Matukas, L. M., Tomlinson, G. A., Rachlis, A. R., Rose, D. B., Dwosh, H. A., Walmsley, S. L., Mazzulli, T., Avendano, M., Derkach, P., and Ephtimios, I. E. (2003). Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA., 289: 2801-2809.

Badawi, A., Ryoo, S. G. (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int. J. Infect. Dis., 49:129-133.

Walters, T. E., Kalman, J. M., Patel, S. K., Mearns, M., Velkoska, E., Burrell, L. M. (2017). Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace, 19:1280–1287.

Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., and Zhang, C. (2020). Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J. Allergy Clin. Immunol.,146(1):110-118.

Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int., 1–10.

Michael, B., Giuseppe, H., Henry, B. M. (2020). Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int. Urol. Nephrol., 2019, 9–10.

Sibbel, S., Sato, R., Hunt, A., Turenne, W., Brunelli, S.M. (2016). The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: A retrospective, observational cohort study. BMC Nephrol., 17, 1–9.

Barry, M., Al-Mohaya, A., AlHijji, A., Akkielah, L., AlRajhi, A., Almajid, F., Alsharidi, A., Al-Shahrani, F. S., Alotaibi, N. H., Alanazi, A. and Ghonem, L. (2020). Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. J. Epidemiol. Glob. Health., 10(3): 214.

Tian, H., Liu, Y., Li, Y., Wu, C. H., Chen, B., Kraemer, M. U., Li, B., Cai, J., Xu, B., Yang, Q., and Wang, B. (2020). An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science, 368(6491): 638-642.

Kim, G. W., Lee, N. R., Pi, R. H. et al. (2015) . IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch. Pharm. Res., 38(5):575–584.

Kotch, C., Barrett, D., Teachey, D. T. (2019). Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert. Rev. Clin. Immunol., 15(8):813–822.

Adhikari, S. P., Meng, S., Wu, Y. J., Mao, Y.-P., Ye, R.-X., Wang, Q.-Z., Sun, C., Sylvia, S., Rozelle, S., Raat, H. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect. Dis. Poverty, 17, 29.

Hu, B., Huang, S., Yin, L. (2021). The cytokine storm and COVID-19. J. Med. Virol.., 93: 250–256.

Ruetsch, C., Brglez, V., Crémoni, M., Zorzi, K., Fernandez, C., Boyer-Suavet, S., Benzaken, S., Demonchy, E., Risso, K., Courjon, J. et al. (2020). Functional exhaustion of Type I and II interferons production in severe COVID-19 patients. Front. Med., 7, 603961.

Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., Wang, L. (2020). Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol., 92: 791–796.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796

Published

25-06-2022

How to Cite

Al-Hatemy, M. D. B., & Mohsin, M. I. (2022). Evaluating the levels of interleukin-6 and interleukin-10 as potential biomarkers for the severity and mortality in COVID-19 patients. International Journal of Health Sciences, 6(S8), 294–310. https://doi.org/10.53730/ijhs.v6nS8.9714

Issue

Section

Peer Review Articles